..
Biogen Idec, Inc. (Massachusetts)
14 Cambridge Center
Cambridge
Massachusetts
02142
U.S.A.
Phone:
617-679-2000
Fax:
617-679-2617
|
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.
Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.
With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.
For product labeling, press releases and additional information about the company, please visit www.biogenidec.com
Email:
Ownership:
Public
Web Site:
Biogen Idec, Inc. (Massachusetts)
Employees:
1700
Symbol: BIIB
|
|
|
Company News |
Biogen Idec, Inc. (Massachusetts) (BIIB) Buys Rights To Eisai Company, Ltd. (ESALY.PK) Alzheimer's Drugs, Amount Undisclosed
3/5/2014 6:32:22 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) To Present At The Cowen and Company 34th Annual Health Care Conference
2/26/2014 6:51:26 AM
More...
|
National Institute for Clinical Excellence (NICE) Turns Down Biogen Idec, Inc. (Massachusetts) (BIIB)'s Oral MS Drug
2/21/2014 7:31:34 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) To Present At The 2014 RBC Capital Markets’ Healthcare Conference
2/19/2014 6:54:29 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Taps Papadopoulos As Its Chairman, Replacing Young
2/17/2014 6:19:51 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Multiple Schlerosis Med TECFIDERA® Wins European Approval
2/3/2014 7:11:34 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) To Report Fourth Quarter And Year-End 2013 Financial Results On January 29, 2014
1/16/2014 6:21:22 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Announces Availability Of FAMPYRA® In Ireland To Treat Walking Impairment In Adults With Multiple Sclerosis
1/15/2014 8:49:36 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) May Pay Sangamo BioSciences, Inc. (SGMO) As Much As $320 Million For Blood Drugs; SGMA Soars +38.32% At Market Close (January 9, 2014)
1/9/2014 7:07:53 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) To Present At The 32nd Annual J.P. Morgan Healthcare Conference
1/8/2014 7:46:39 AM
More...
|
|
|
|